Mariangela Rubino

Dr. Mariangela Rubino

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
TFTeresa Vanessa Fiorentino
Teresa Vanessa Fiorentino
FVFrancesca De Vito
Francesca De Vito
MNMaria Resilde Natale
Maria Resilde Natale
SSSilvia Sergi
Silvia Sergi
MRMariangela Rubino
Mariangela Rubino
GSGiorgio Sesti
Giorgio Sesti
Recently, the International Diabetes Federation (IDF) has recommended determination of 1 h-post-load glucose (PG) to diagnose intermediate hyperglycemia (IH) and type 2 diabetes (T2DM). Herein, we investigate the implication of IDF recommendation in identifying subjects with chronic kidney disease (CKD). Estimated glomerular filtration rate (eGFR) was assessed on 2161 subjects classified on the basis of their fasting, 1 h and 2 h-PG, according to the IDF criteria, as having normal glucose tolerance (NGT), isolated impaired fasting glucose (iIFG), IH and T2DM. Prevalence of CKD (eGFR < 60 ml/min/1.73 m2) and mildly reduced kidney function (eGFR 90-60 ml/min/1.73 m2) progressively increased at worsening of glucose tolerance. In a logistic regression analysis adjusted for several cardio-metabolic confounders, individuals with iIFG and IH exhibited a 3.48- (95 %CI = 1.01-11.00, P = 0.05) and 3.69- (95 %CI = 1.42-9.60, P = 0.007) fold increased risk of having CKD compared to the NGT group. The risk for CKD was further increased in subjects with T2DM (OR = 3.93, 95 %CI = 1.36-10.66, P = 0.007). Additionally, participants with IH and T2DM had a 1.89-fold (95 %CI = 1.38-2.60, P < 0.0001) and 2.78-fold (95 %CI = 1.97-3.98, P < 0.0001) higher risk of mildly reduced GFR compared to the NGT group. The 1 h-PG thresholds proposed by IDF as diagnostic for IH and T2DM are capable of identifying individuals at risk of kidney dysfunction.

25 September 2021 in Medicina
Verified
Journal Article
Open access
PDF file
Alessandro de SireAlessandro de Sire
Alessandro de Sire
MIMaria Teresa Inzitari
Maria Teresa Inzitari
LMLucrezia Moggio
Lucrezia Moggio
MPMonica Pinto
Monica Pinto
GSGiustino de Sire
Giustino de Sire
Francesco AndreozziFrancesco Andreozzi
Francesco Andreozzi
Background and Objectives: Diabetes mellitus type 2 (T2DM) is a chronic disease associated with fluid accumulation in the interstitial tissue. Manual lymphatic drainage (MLD) plays a role in reducing lymphoedema, like intermittent pneumatic compression (IPC). By the present pilot study, we aimed to evaluate the efficacy of a synergistic treatment with MLD and IPC in reducing lower limb lymphedema in T2DM patients. Materials and Methods: Adults with a clinical diagnosis of T2DM and lower limb lymphedema (stage II–IV) were recruited from July to December 2020. Study participants were randomized into two groups: experimental group, undergoing a 1-month rehabilitative program consisting of MLD and IPC (with a compression of 60 to 80 mmHg); control group, undergoing MLD and a sham IPC (with compression of <30 mmHg). The primary outcome was the lower limb lymphedema reduction, assessed by the circumferential method (CM). Secondary outcomes were: passive range of motion (pROM) of hip, knee, and ankle; quality of life; laboratory exams as fasting plasma glucose and HbA1c. At baseline (T0) and at the end of the 1-month rehabilitative treatment (T1), all the outcome measures were assessed, except for the Hb1Ac evaluated after three months. Results: Out of 66 T2DM patients recruited, only 30 respected the eligibility criteria and were randomly allocated into 2 groups: experimental group (n = 15; mean age: 54.2 ± 4.9 years) and control group (n = 15; mean age: 54.0 ± 5.5 years). At the intra-group analysis, the experimental group showed a statistically significant improvement of all outcome measures (p < 0.05). The between-group analysis showed a statistically significant improvement in pROM of the hip, knee, ankle, EQ-VAS, and EQ5D3L index at T1. Conclusions: A multimodal approach consisting of IPC and MLD showed to play a role in reducing lower limb lymphedema, with an increase of pROM and HRQoL. Since these are preliminary data, further studies are needed.

29 December 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
EMElettra Mancuso
Elettra Mancuso
RSRosangela Spiga
Rosangela Spiga
MRMariangela Rubino
Mariangela Rubino
CACarolina Averta
Carolina Averta
SRSalvatore Rotundo
Salvatore Rotundo
FAFrancesco Andreozzi
Francesco Andreozzi

26 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MMMattia Massimino
Mattia Massimino
MRMariangela Rubino
Mariangela Rubino
MNMaria Resilde Natale
Maria Resilde Natale
LSLuca Salerno
Luca Salerno
SBStefania Belviso
Stefania Belviso
Francesco AndreozziFrancesco Andreozzi
Francesco Andreozzi
Background: Type 2 diabetes mellitus represents a global health challenge, with chronic hyperglycemia leading to a spectrum of microvascular and macrovascular complications. This narrative review provides a comprehensive and integrated analysis of the nerve growth factor (NGF) axis as a key, yet underrecognized, pathogenic mechanism. Methods: This narrative review was conducted in accordance with scholarly standards for non-systematic syntheses (SANRA). We included both clinical and preclinical studies focusing on NGF/proNGF biology and interventions across major diabetes complications. Discussion: Growing evidence highlights NGF as a pivotal mediator at the crossroads of neuronal, vascular and metabolic pathways. In diabetes, a disrupted balance between mature NGF and its precursor proNGF, favors the detrimental p75NTR pathway, leading to increased cellular stress, inflammation and apoptosis. In this narrative review, we examine how a decline in mature NGF and a relative excess of proNGF contribute to the pathophysiology of diabetic complications across various organ systems. We highlight the dual role of the NGF axis: while NGF-TrkA signaling consistently confers neuroprotective and vasculoprotective benefits, unchecked proNGF-p75NTR activity amplifies tissue damage. Conclusions: Collectively, the evidence identifies NGF as a candidate biomarker for both early tissue distress and therapeutic monitoring. We conclude by outlining key priorities for future research, including the development of standardized assays and the initiation of well-designed clinical trials to translate these promising strategies for early detection and treatment of diabetes-related complications.

13 October 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
ADAntonella Desiderio
Antonella Desiderio
EMElettra Mancuso
Elettra Mancuso
GMGaia Chiara Mannino
Gaia Chiara Mannino
MPMonica Pastorino
Monica Pastorino
CNCecilia Nigro
Cecilia Nigro
FAFrancesco Andreozzi
Francesco Andreozzi